Adjuvant therapy for hepatocellular carcinoma: Dilemmas at the start of a new era

doi:10.3748/wjg.v30.i8.806

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1210)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

WORD

HTML

851

Figures (1-1)

Sum=1024

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=120

Feb 28, 2024 (publication date) through Apr 27, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Feb 28, 2024; 30(8): 806-810
Published online Feb 28, 2024. doi: 10.3748/wjg.v30.i8.806

Adjuvant therapy for hepatocellular carcinoma: Dilemmas at the start of a new era

Jian-Hong Zhong

Jian-Hong Zhong, Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, Guangxi Zhuang Autonomous Region, China

Author contributions: Zhong JH wrote and revised the manuscript.

Supported by the Specific Research Project of Guangxi for Research Bases and Talents, No. GuiKe AD22035057; and the National Natural Science Foundation of China, No. 82060510 and No. 82260569.

Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Jian-Hong Zhong, Doctor, PhD, Academic Editor, Doctor, Professor, Surgeon, Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, No. 71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. zhongjianhong@gxmu.edu.cn

Received: December 10, 2023
Peer-review started: December 10, 2023
First decision: December 27, 2023
Revised: December 27, 2023
Accepted: January 31, 2024
Article in press: January 31, 2024
Published online: February 28, 2024

Core Tip

Core Tip: Several questions need to be addressed by clinical researchers about the use of adjuvant therapy to prolong recurrence-free survival of patients with hepatocellular carcinoma following potentially curative treatment.